Pfizer Outperforms Expectations, Charts Post-Pandemic Course

Pfizer delivered a stronger-than-anticipated fourth quarter, surpassing Wall Street forecasts even as sales of its Covid-19 products continued to soften. The company simultaneously reaffirmed its full-year 2026 financial outlook, a projection that initially disappointed the market last December.

The pharmaceutical leader reported adjusted earnings of 66 cents per share on revenue of $17.56 billion, beating analyst estimates. Despite the quarterly outperformance, revenue dipped slightly year-over-year, a decline Pfizer attributes primarily to reduced demand for its Covid vaccine and the antiviral treatment Paxlovid. The quarter resulted in a net loss of $1.65 billion, driven by significant restructuring and acquisition-related charges.

Looking ahead, Pfizer is navigating a transition. It expects 2026 revenue to be roughly flat compared to 2025, anticipating an approximate $3 billion combined decline from Covid products and older medicines losing patent protection. To fuel future growth, the company is emphasizing cost-cutting initiatives and new acquisitions, notably its $10 billion purchase of the obesity drug developer Metsera. Early data on a once-monthly Metsera injection showed promising weight loss results.

A key factor in Pfizer's modest margin outlook is a major drug pricing agreement with the Trump administration, finalized after the President's 2025 election. The deal requires Pfizer to offer its lowest international prices to Medicaid and extends similar "most-favored-nation" terms to other government and commercial payers. In exchange, the company receives a three-year tariff exemption. This policy, alongside the selection of its arthritis drug Xeljanz for Medicare price negotiations, shapes the company's financial landscape as it seeks to rebuild its product portfolio beyond the pandemic era.

Source: CNBC